Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.63 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.54 |
| ▸ | BCHE | P06276 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.50 |
| ▸ | BACE1 | P56817 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | GBA1 | P04062 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.45 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.45 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4766363 | 1.00 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3GRIN2BBCHE | |
| SCHEMBL605459 | 1.00 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3GRIN2BBCHE | |
| Hydrochloric Acid SCHEMBL697481 | 0.98 | SLC6A2 (0.61) | SLC6A2SLC6A4SLC6A3GRIN2BBCHE | |
| Hydrochloric Acid SCHEMBL697480 | 0.98 | SLC6A2 (0.61) | SLC6A2SLC6A4SLC6A3GRIN2BBCHE | |
| SCHEMBL994345 | 0.90 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3GRIN2BBCHE | |
| SCHEMBL2687312 | 0.90 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3GRIN2BBCHE | |
| SCHEMBL658055 | 0.89 | GRIN2B (0.62) | SLC6A2SLC6A4SLC6A3GRIN2BBCHE | |
| SCHEMBL4696319 | 0.88 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3GRIN2BBCHE | |
| Hydrochloric Acid SCHEMBL5238529 | 0.87 | GRIN2B (0.61) | SLC6A2SLC6A4SLC6A3GRIN2BBCHE | |
| SCHEMBL8186106 | 0.85 | GRIN2B (0.56) | SLC6A2SLC6A4SLC6A3GRIN2BBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| US-20230406885-A1 | CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2023-12-21 | — | — | US | disclosed |
| EP-2022852-B1 | METHOD FOR PRODUCTION OF OPTICALLY ACTIVE AMINE COMPOUND, RECOMBINANT VECTOR, AND TRANSFORMANT CARRYING THE VECTOR | KANEKA CORP (JP) | 2017-07-05 | — | — | EP | disclosed |
| US-8569294-B2 | 2-(cyclic amino)-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-10-29 | — | — | US | disclosed |
| US-8569294-B2 | 2-(cyclic amino)-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-10-29 | — | — | US | disclosed |
| US-8318750-B2 | Organic compounds | NOVARTIS AG (NL) | 2012-11-27 | — | — | US | disclosed |
| EP-2523957-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2012-11-21 | — | — | EP | disclosed |
| US-8258141-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| US-8168412-B2 | Method for producing optically-active amine compound, recombinant vector, and transformant containing the vector | KANEKA CORPORATION (JP) | 2012-05-01 | — | — | US | disclosed |
| EP-2013211-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| EP-0991753-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-04-12 | — | — | EP | disclosed |
| EP-0912175-A4 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 1999-09-08 | — | — | EP | disclosed |
| EP-0912175-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 1999-05-06 | — | — | EP | disclosed |
| US-5854245-A | Fibrinogen receptor antagonists | MERCK & CO., INC. (US) | 1998-12-29 | — | — | US | disclosed |
| WO-1998050534-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-12 | — | — | WO | disclosed |
| EP-0871628-A1 | QUINOLIZINONE TYPE COMPOUNDS | Abbott Laboratories (US) | 1998-10-21 | — | — | EP | disclosed |
| US-5726182-A | TREATMENT OF BACTERIAL INFECTIONS | ABBOTT LABORATORIES (US) | 1998-03-10 | — | — | US | disclosed |
| WO-1998000134-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1998-01-08 | — | — | WO | disclosed |
| US-5599816-A | BACTERICIDE | ABBOTT LABORATORIES (US) | 1997-02-04 | — | — | US | disclosed |
| WO-1996039407-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406885-A1 | CYCLIC PEPTIDES FOR TRAPPING INTERLEUKIN-1 BETA | IL1A, IL1B, IL1R1 | SLC6A2 4533/4885SLC6A4 4716/4885SLC6A3 4318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.